幽门螺杆菌感染对 PD-1/PD-L1 阻断治疗的影响需要更多关注。
Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
机构信息
Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
出版信息
Helicobacter. 2022 Apr;27(2):e12878. doi: 10.1111/hel.12878. Epub 2022 Feb 3.
BACKGROUND AND OBJECTIVE
The tumor microenvironment and tumor immunity are crucially involved in tumor therapy. Immune checkpoint inhibitors targeting PD-1/PD-L1 signal transduction have been widely used in tumor therapy and have shown ideal clinical efficacy. However, some kinds of cancers still do not respond to PD-1/PD-L1 blockade therapy effectively, including gastric cancer. The related factors should be explored.
METHODS AND RESULTS
This review summarizes the recent progression of understanding the influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy. Current pieces of evidence have indicated that H. pylori infection might affect the curative effect of tumor therapy associating with the induced immunomodulation.
CONCLUSION
It is necessary to understand the overall integration of PD-1/PD-L1 blockade therapy, the tumor microenvironment, and H. pylori infection. Much attention on the influence of H. pylori infection on the efficacy of tumor immunotherapy should be paid.
背景与目的
肿瘤微环境和肿瘤免疫在肿瘤治疗中起着至关重要的作用。针对 PD-1/PD-L1 信号转导的免疫检查点抑制剂已广泛应用于肿瘤治疗，并显示出理想的临床疗效。然而，某些类型的癌症对 PD-1/PD-L1 阻断治疗仍然没有有效反应，包括胃癌。需要探讨相关因素。
方法和结果
本综述总结了目前对幽门螺杆菌感染对 PD-1/PD-L1 阻断治疗影响的认识进展。目前的证据表明，幽门螺杆菌感染可能通过诱导免疫调节来影响肿瘤治疗的疗效。
结论
有必要了解 PD-1/PD-L1 阻断治疗、肿瘤微环境和幽门螺杆菌感染的整体综合情况。应更加关注幽门螺杆菌感染对肿瘤免疫治疗疗效的影响。
Zotero 插件